Latest News in the pharma Industry

Top Stories

Cardiolynx Receives Patent on Improved Angina Pectoris Drug

Cardiolynx Receives Patent on Improved Angina Pectoris Drug

20 Sep 2012

Cardiolynx Ltd., specializing in the development of improved cardio-metabolic therapies, announces that the European Patent Office (EPO) has granted a patent covering a new chemical entity, CLC-1280, developed using Cardiolynx' nitric oxide technology.

Read more 
Mucosis Appoints Thomas Johnston to CEO

Mucosis Appoints Thomas Johnston to CEO

18 Sep 2012

Mucosis B.V., the Dutch clinical-stage biotechnology company developing mucosal vaccines, today announced the appointment of Thomas Johnston to the position of Chief Executive Officer, effective immediately.

Read more 
RepliGen Europe Limited withdraws its marketing authorisation application for SecreFlo (secretin human)

RepliGen Europe Limited withdraws its marketing authorisation application for SecreFlo (secretin human)

17 Sep 2012

The European Medicines Agency has been formally notified by RepliGen Europe Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine SecreFlo (secretin human).

Read more 
Committee for Orphan Medicinal Products elects new chair and vice-chair

Committee for Orphan Medicinal Products elects new chair and vice-chair

17 Sep 2012

At its September 2012 meeting, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) elected Professor Bruno Sepodes from Portugal as its chair and Ms Lesley Greene, a volunteer patient representative for Eurordis, as its vice-...

Read more 
European Medicines Agency clarifies rules on fees

European Medicines Agency clarifies rules on fees

17 Sep 2012

The European Medicines Agency has revised the rules on fees payable to the Agency.

Read more 
Stella Blackburn appointed president of the International Society for Pharmacoepidemiology

Stella Blackburn appointed president of the International Society for Pharmacoepidemiology

17 Sep 2012

The European Medicines Agency congratulates Dr Stella Blackburn, the Agency's Risk Management Development and Scientific Lead, for her appointment as president of the International Society for Pharmacoepidemiology (ISPE).

Read more 
Pharmacovigilance Risk Assessment Committee (PRAC) elects chair and vice-chair

Pharmacovigilance Risk Assessment Committee (PRAC) elects chair and vice-chair

17 Sep 2012

The European Medicines Agency’s recently established Pharmacovigilance Risk Assessment Committee (PRAC) has elected June Raine (pictured) from the United Kingdom (UK) as its chair and álmath Spooner from Ireland as its vice-chair at its second mee...

Read more 
Big Pharma Fights Drug Rulings In India

Big Pharma Fights Drug Rulings In India

17 Sep 2012

Landmark drug patent protection cases involving Bayer, Roche, and Novartis are advancing in India this month. Together, they will help determine how friendly the country is to Western pharmaceutical makers.

Read more 
AESICA ANNOUNCES KEY NORTH AMERICAN APPOINTMENT

AESICA ANNOUNCES KEY NORTH AMERICAN APPOINTMENT

14 Sep 2012

One of Europe’s leading CMOs, Aesica, has announced a key addition to its commercial team as it looks to strengthen its position in North America.

Read more 
Possible therapy for tamoxifen-resistant breast cancer identified

Possible therapy for tamoxifen-resistant breast cancer identified

6 Sep 2012

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

Read more 
Pfizer leukaemia drug receives US approval

Pfizer leukaemia drug receives US approval

6 Sep 2012

The US Food and Drug Administration has approved Pfizer's Bosulif, used to treat a rare type of leukaemia usually suffered by older adults.

Read more 
FDA questions efficacy of Novartis cystic fibrosis drug tobramycin

FDA questions efficacy of Novartis cystic fibrosis drug tobramycin

6 Sep 2012

The US Food and Drug Administration has questioned the efficacy of Novartis' experimental cystic fibrosis drug tobramycin ahead of an advisory panel meeting this week.

Read more